علاج الخط الأول لسرطان الغدد اللمفاوية الكبيرة اللاتمايزية إيجابي ALK

References

1. First-line treatment of ALK-positive ALCL:
2. In patients with limited-stage, non-bulky disease and a favourable pre-therapeutic risk profile, abbreviated ChT (e.g. three to four cycles of BV-CHP or CHOEP) [III, B] followed by consolidative ISRT (e.g. 30-40 Gy) in responding patients [IV, B] can be recommended.
3. All other ChT-eligible patients should be offered six cycles of BV-CHP [I, A].
4. Six cycles of CHO(E)P is an alternative for patients with stage I-II high-risk (bulky disease, IPI ≥2 or age >40 years) or advanced-stage disease [III, B].
5. Consolidative ISRT can be recommended for patients with stage I-II, high-risk disease after six cycles of BV-CHP or CHO(E)P [IV, B].
6. ASCT is generally not recommended for patients with stage III-IV low-risk disease [III, D].
7. It can, however, be considered for patients with stage I-IV disease with high-risk features (e.g. IPI 3-4 and/or bulky extranodal disease and/or unconfirmed suspected residual disease activity) [II, B].

DOI: 10.1016/j.annonc.2025.07.014

View source ↗